187 related articles for article (PubMed ID: 35105642)
1. Prevalence and incidence of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium during 1 year of the COVID-19 epidemic: prospective cohort study protocol.
Adriaenssens N; Scholtes B; Bruyndonckx R; Verbakel JY; De Sutter A; Heytens S; Van den Bruel A; Desombere I; Van Damme P; Goossens H; Buret L; Duysburgh E; Coenen S
BMJ Open; 2022 Jan; 12(1):e054688. PubMed ID: 35105642
[TBL] [Abstract][Full Text] [Related]
2. Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up.
Adriaenssens N; Scholtes B; Bruyndonckx R; Van Ngoc P; Verbakel JYJ; De Sutter A; Heytens S; Van Den Bruel A; Desombere I; Van Damme P; Goossens H; Buret L; Duysburgh E; Coenen S
BMJ Open; 2022 Sep; 12(9):e065897. PubMed ID: 36123069
[TBL] [Abstract][Full Text] [Related]
3. Prospective SARS-CoV-2 cohort study among primary health care providers during the second COVID-19 wave in Flanders, Belgium.
Mariën J; Ceulemans A; Bakokimi D; Lammens C; Ieven M; Heytens S; De Sutter A; Verbakel JY; Van den Bruel A; Goossens H; Van Damme P; Ariën KK; Coenen S
Fam Pract; 2022 Jan; 39(1):92-98. PubMed ID: 34448859
[TBL] [Abstract][Full Text] [Related]
4. Validation of a rapid SARS-CoV-2 antibody test in general practice.
Domen J; Verbakel JYJ; Adriaenssens N; Scholtes B; Peeters B; Bruyndonckx R; De Sutter A; Heytens S; Van den Bruel A; Desombere I; Van Damme P; Goossens H; Buret L; Duysburgh E; Coenen S
BMJ Open; 2023 May; 13(5):e069997. PubMed ID: 37130685
[TBL] [Abstract][Full Text] [Related]
5. University population-based prospective cohort study of SARS-CoV-2 infection and immunity (SARSSURV-ULiège): a study protocol.
Donneau AF; Guillaume M; Bours V; Dandoy M; Darcis G; Desmecht D; Diep AN; Fievez L; Garigliany MM; Gillain N; Husson E; Michel F; Moutschen M; Paridans M; Benoît P; Sabatel C; Saegerman C; Tytgat A; Gillet L; Bureau F
BMJ Open; 2022 Jan; 12(1):e055721. PubMed ID: 35078848
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and incidence of anti-SARS-CoV-2 antibodies among healthcare workers in Belgian hospitals before vaccination: a prospective cohort study.
Mortgat L; Verdonck K; Hutse V; Thomas I; Barbezange C; Heyndrickx L; Fischer N; Vuylsteke B; Kabouche I; Ariën KK; Desombere I; Duysburgh E
BMJ Open; 2021 Jun; 11(6):e050824. PubMed ID: 34187832
[TBL] [Abstract][Full Text] [Related]
7. Monitoring of SARS-CoV-2 seroprevalence among primary healthcare patients in the Barcelona Metropolitan Area: the SeroCAP sentinel network protocol.
Sentís A; Torán P; Esperalba J; Agustí C; Ángel M; Fernández MG; Dopico E; Salvador-González B; González MV; Bordas A; Antón A; Violan C; Montoro-Fernández M; Aceiton J; Egea-Cortés L; Alonso L; Dacosta-Aguayo R; Calatayud L; Lejardi Y; Mendioroz J; Basora J; Reyes-Urueña J; Casabona J
BMJ Open; 2022 Feb; 12(2):e053237. PubMed ID: 35140153
[TBL] [Abstract][Full Text] [Related]
8. Impact of prior SARS-CoV-2 infection and COVID-19 vaccination on the subsequent incidence of COVID-19: a multicentre prospective cohort study among UK healthcare workers - the SIREN (Sarscov2 Immunity & REinfection EvaluatioN) study protocol.
Wallace S; Hall V; Charlett A; Kirwan PD; Cole M; Gillson N; Atti A; Timeyin J; Foulkes S; Taylor-Kerr A; Andrews N; Shrotri M; Rokadiya S; Oguti B; Vusirikala A; Islam J; Zambon M; Brooks TJG; Ramsay M; Brown CS; Chand M; Hopkins S
BMJ Open; 2022 Jun; 12(6):e054336. PubMed ID: 35768083
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol.
Bachelet VC; Silva-Ayarza I; Lizana FJ; Gomolán P; Silva-Villalobos D; Navarrete MS
BMJ Open; 2022 May; 12(5):e061345. PubMed ID: 35589344
[TBL] [Abstract][Full Text] [Related]
10. The seroprevalence of SARS-CoV-2 in a rural southwest community.
Santarelli A; Lalitsasivimol D; Bartholomew N; Reid S; Reid J; Lyon C; Wells J; Ashurst J
J Osteopath Med; 2021 Feb; 121(2):199-210. PubMed ID: 33567087
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of SARS-CoV-2 infection and dynamics of antibodies response among previously undiagnosed healthcare workers in a university hospital: A prospective cohort study.
Musa S; Abdel Alem S; Amer K; Elnagdy T; Hassan WA; Ali MA; Gaber Y; Badary HA; Tantawi O; Abdelmoniem R; Radwan A; Yousof H; Shawky S; Talaat H; Fouad R; Kassem AM
J Infect Public Health; 2021 Oct; 14(10):1466-1473. PubMed ID: 34175238
[TBL] [Abstract][Full Text] [Related]
12. Specchio-COVID19 cohort study: a longitudinal follow-up of SARS-CoV-2 serosurvey participants in the canton of Geneva, Switzerland.
Baysson H; Pennachio F; Wisniak A; Zabella ME; Pullen N; Collombet P; Lorthe E; Joost S; Balavoine JF; Bachmann D; Azman A; Pittet D; Chappuis F; Kherad O; Kaiser L; Guessous I; Stringhini S;
BMJ Open; 2022 Jan; 12(1):e055515. PubMed ID: 35105645
[TBL] [Abstract][Full Text] [Related]
13. SARS-CoV-2 infection prevention and control measures in Belgian schools between December 2020 and June 2021 and their association with seroprevalence: a cross-sectional analysis of a prospective cohort study.
Callies M; Kabouche I; Desombere I; Merckx J; Roelants M; Vermeulen M; Duysburgh E
BMC Public Health; 2023 May; 23(1):898. PubMed ID: 37194008
[TBL] [Abstract][Full Text] [Related]
14. Seroprevalence of SARS-CoV-2 antibodies in children of United Kingdom healthcare workers: a prospective multicentre cohort study protocol.
Corr M; Christie S; Watson C; Maney J; Fairley D; Ladhani SN; Lyttle MD; McFetridge L; Mitchell H; Shields MD; McGinn C; McKenna J; Mallett P; Ferris K; Rowe-Setz G; Moore R; Foster S; Evans J; Waterfield T
BMJ Open; 2020 Nov; 10(11):e041661. PubMed ID: 33444212
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive infection control measures prevent hospital-acquired severe acute respiratory syndrome coronavirus 2 infection: A single-center prospective cohort study and seroprevalence survey.
Hori H; Fukuchi T; Sanui M; Moriya T; Sugawara H
PLoS One; 2021; 16(10):e0257513. PubMed ID: 34634076
[TBL] [Abstract][Full Text] [Related]
16. Half-Year Longitudinal Seroprevalence of SARS-CoV-2-Antibodies and Rule Compliance in German Hospital Employees.
Herzberg J; Vollmer T; Fischer B; Becher H; Becker AK; Sahly H; Honarpisheh H; Guraya SY; Strate T; Knabbe C
Int J Environ Res Public Health; 2021 Oct; 18(20):. PubMed ID: 34682719
[TBL] [Abstract][Full Text] [Related]
17. SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey.
Hoballah A; El Haidari R; Siblany G; Abdel Sater F; Mansour S; Hassan H; Abou-Abbas L
BMC Infect Dis; 2022 Jan; 22(1):42. PubMed ID: 35012464
[TBL] [Abstract][Full Text] [Related]
18. SARS-CoV-2 seroprevalence survey among health care providers in a Belgian public multiple-site hospital.
Naesens R; Mertes H; Clukers J; Herzog S; Brands C; Vets P; De Laet I; Bruynseels P; De Schouwer P; van der Maas S; Bervoets K; Hens N; Van Damme P
Epidemiol Infect; 2021 Aug; 149():e172. PubMed ID: 34372955
[TBL] [Abstract][Full Text] [Related]
19. PEP-CoV protocol: a PEP flute-self-care randomised controlled trial to prevent respiratory deterioration and hospitalisation in early COVID-19.
Mollerup A; Larsen SC; Bennetzen AS; Henriksen M; Simonsen MK; Weis N; Kofod LM; Heitmann BL
BMJ Open; 2021 Jun; 11(6):e050582. PubMed ID: 34193503
[TBL] [Abstract][Full Text] [Related]
20. Protocol of the Luebeck longitudinal investigation of SARS-CoV-2 infection (ELISA) study - a prospective population-based cohort study.
Balck A; Föh B; Borsche M; Rahmöller J; Vollstedt EJ; Waldeck F; Käding N; Twesten C; Mischnik A; Gillessen-Kaesbach G; Ehlers M; Sina C; Taube S; Busch H; Rupp J; Katalinic A; Klein C
BMC Public Health; 2022 Jul; 22(1):1305. PubMed ID: 35799167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
